The benefit of whole brain reirradiation in patients with multiple brain metastases

Radiation Oncology

Ufuk Abacioglu⁵  Faysal Dane¹  Askin Seker³  Aysegul Ucuncu Kefeli²  Beste M Atasoy²  Zerrin Ozgen⁴ 

[1] Marmara University School of Medicine Department of Internal Medicine Division of Medical Oncology, Istanbul, Turkey;Marmara University School of Medicine Department of Radiation Oncology, Istanbul, Turkey;Marmara University School of Medicine Department of Neurosurgery, Istanbul, Turkey;MH-Marmara University Pendik Education and Research Hospital Radiation Oncology Clinic, Fevzi Cakmak mah, Mimar Sinan cad. No. 41 34899, Ust Kaynarca Pendik, Istanbul, Turkey;Neolife Medical Center Radiotherapy Clinic, Istanbul, Turkey

关键词: Whole brain radiotherapy;    Reirradiation;    Cancer;    Brain metastases;   

Others  :  1153328
DOI  :  10.1186/1748-717X-8-186

 received in 2013-05-07, accepted in 2013-07-21,  发布年份 2013

【 摘 要 】

Background

To assess the outcomes, symptom palliation and survival rates in patients who received repeat whole brain radiotherapy (WBRT).

Methods

Twenty-eight patients who had progression of brain metastasis received a second course of WBRT. Univariate log-rank testing and multivariate Cox regression analysis were used to determine the factors for death among several variables (cumulative BED [BEDcumulative], primary tumor site, Karnofsky performance scale [KPS], previous SRS, number of metastases and absence of extracranial metastases). Correlations between variables and treatment response were evaluated with the Chi-squared test.

Results

The median KPS was 60 (range 50 to 100) at the initiation of reirradiation. The median time interval between the two courses of WBRT was 9.5 months (range 3–27 months). The median doses of the first course and the second course of WBRT were 30 Gy (range 20 to 30 Gy) and 25 Gy (range 20 to 30 Gy), respectively. The mean BEDcumulative was 129.5 Gy (range 110 to 150 Gy). Severe or unexpected toxicity was not observed. Symptomatic response was detected in 39% of the patients. The median overall survival following reirradiation was 3 months (range 1 to 12 months, 95% CI 1.82-4.118). Survival was significantly better in responders (median 10 months, 95% CI 3.56-16.43) compared with non-responders (median 2 months, 95% CI 1.3-2.64) (p = 0.000). In multivariate analysis, patients that had lung cancer (p = 0.01), initial KPS ≥60 (p = 0.03) or longer intervals to reirradiation (p = 0.01) had significantly better survival rates.

Conclusions

A careful second course of whole brain irradiation might provide a symptomatic and survival benefit in patients with good performance status and longer cranial progression-free intervals.

【 授权许可】

   
2013 Ozgen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Gavrilovic IT, Posner JB: Brain metastases: epidemiology and pathophysiology. J Neurooncol 2005, 75:5-14.
• [2]Schouten LJ, Rutten J, Huveneers HA, Twijnstra A: Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002, 94:2698-2705.
• [3]Sundstrom JT, Minn H, Lertola KK, Nordman E: Prognosis of patients treated for intracranial metastases with whole-brain irradiation. Ann Med 1998, 30:296-299.
• [4]Sperduto PW: What is your patient’s GPA and why does it matter? Managing brain metastases and the cost of hope. Int J Radiat Oncol Biol Phys 2010, 77:643-644.
• [5]Ammirati M, Cobbs CS, Linskey ME, et al.: The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010, 96:85-96.
• [6]Sengoz KM, Abacioglu MU, Atasoy BM: Survival and prognostic factor analysis in whole brain irradiation of patients with brain metastases. Marmara Med J 2001, 14:7-11.
• [7]Mayer R, Sminia P: Reirradiation tolerance of human brain. Int J Radiat Oncol Biol Phys 2008, 70:1350-1360.
• [8]Fowler JF: 21 years of biologically effective dose. Br J Radiol 2010, 83:554-568.
• [9]Sadikov E, Bezjak A, Yi QL, et al.: Value of whole brain reirradiation for brain metastases: Single centre experience. Clin Oncol (R Coll Radiol) 2007, 19:532-538.
• [10]Hazuka MB, Kinzie JJ: Brain metastases: Results and effects of re-irradiation. Int J Radiat Oncol Biol Phys 1988, 15:433-437.
• [11]Cooper JS, Steinfeld AD, Lerch IA: Cerebral metastases: Value of reirradiation in selected patients. Radiology 1990, 174:883-885.
• [12]Wong WW, Schild SE, Sawyer TE, et al.: Analysis of outcome in patients reirradiated for brain metastases. Int J Radiat Oncol Biol Phys 1996, 34:585-590.
• [13]Son CH, Jimenez R, Niemierko A, Loeffler JS, Oh KS, Shih HA: Outcomes after whole brain reirradiation in patients with brain metastases. Int J Radiat Oncol Biol Phys 2012, 82:e167-e172.
• [14]Abdel-Wahab MM, Wolfson AH, Raub W, et al.: The role of hyperfractionated re-irradiation in metastatic brain disease: a single institutional trial. Am J Clin Oncol 1997, 20:158-160.